

Table 41. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2003¹

Reporting Area	Total Cases	Therapy ≤1 Year Indicated ²		Therapy >1 Year Indicated ³		All Drug Therapy		
		No. ⁴	COT ≤1 Year(%) COT(%)	No. ⁴	COT(%)	No. ⁴	COT(%)	
United States	14,840	13205	(81.5)	(92.2)	195	(78.5)	13400	(92.0)
Alabama	258	235	(85.1)	(94.9)	1	(100.0)	236	(94.9)
Alaska	57	52	(90.4)	(98.1)	1	(100.0)	53	(98.1)
Arizona	295	260	(79.2)	(82.7)	2	(0.0)	262	(82.1)
Arkansas	128	116	(87.1)	(94.0)	1	(100.0)	117	(94.0)
California	3,220	2876	(80.0)	(92.2)	57	(80.7)	2933	(92.0)
Colorado	111	102	(93.1)	(96.1)	3	(100.0)	105	(96.2)
Connecticut	111	101	(73.3)	(92.1)	0	...	101	(92.1)
Delaware	32	28	(85.7)	(100.0)	0	...	28	(100.0)
District of Columbia	79	68	(91.2)	(97.1)	0	...	68	(97.1)
Florida	1,041	922	(85.4)	(96.4)	12	(75.0)	934	(96.1)
Georgia	532	484	(77.9)	(89.7)	3	(66.7)	487	(89.5)
Hawaii	116	99	(76.8)	(93.9)	5	(20.0)	104	(90.4)
Idaho	13	13	—	—	0	...	13	—
Illinois	632	567	(80.4)	(90.3)	8	(87.5)	575	(90.3)
Indiana	143	118	(95.8)	(98.3)	2	(50.0)	120	(97.5)
Iowa	40	36	(91.7)	(100.0)	1	(100.0)	37	(100.0)
Kansas	75	65	(76.9)	(87.7)	2	(50.0)	67	(86.6)
Kentucky	138	120	(85.0)	(95.0)	1	(100.0)	121	(95.0)
Louisiana	256	219	(79.9)	(92.7)	1	(100.0)	220	(92.7)
Maine	24	23	(69.6)	(95.7)	0	...	23	(95.7)
Maryland	269	242	(86.8)	(95.5)	3	(100.0)	245	(95.5)
Massachusetts	261	247	(76.5)	(95.5)	0	...	247	(95.5)
Michigan	243	211	(83.4)	(92.4)	4	(75.0)	215	(92.1)
Minnesota	214	201	(88.6)	(96.5)	4	(100.0)	205	(96.6)
Mississippi	131	112	(76.8)	(92.9)	2	(100.0)	114	(93.0)
Missouri	130	107	(71.0)	(90.7)	2	(100.0)	109	(90.8)
Montana	7	5	(100.0)	(100.0)	1	(100.0)	6	(100.0)
Nebraska	28	26	(69.2)	(76.9)	0	...	26	(76.9)
Nevada	106	96	(91.7)	(95.8)	3	(66.7)	99	(94.9)
New Hampshire	15	14	(85.7)	(92.9)	0	...	14	(92.9)
New Jersey	495	456	(80.0)	(91.7)	7	(57.1)	463	(91.1)
New Mexico	49	37	(86.5)	(100.0)	1	(100.0)	38	(100.0)
New York State ⁵	340	301	(81.1)	(95.0)	4	(100.0)	305	(95.1)
New York City	1,131	998	(85.6)	(93.3)	21	(76.2)	1019	(92.9)
North Carolina	374	324	(89.2)	(95.7)	1	(100.0)	325	(95.7)
North Dakota	6	4	(25.0)	(75.0)	0	...	4	(75.0)
Ohio	229	194	(88.7)	(93.8)	2	(100.0)	196	(93.9)
Oklahoma	163	137	(69.3)	(94.2)	1	(100.0)	138	(94.2)
Oregon	106	99	(81.8)	(93.9)	1	(100.0)	100	(94.0)
Pennsylvania	336	290	(79.3)	(91.0)	2	(0.0)	292	(90.4)
Rhode Island	46	40	(90.0)	(95.0)	0	...	40	(95.0)
South Carolina	254	234	(85.5)	(93.6)	1	(100.0)	235	(93.6)
South Dakota	20	15	(73.3)	(93.3)	1	(100.0)	16	(93.8)
Tennessee	286	238	(79.8)	(91.2)	3	(100.0)	241	(91.3)
Texas	1,580	1411	(74.8)	(84.9)	25	(76.0)	1436	(84.7)
Utah	39	34	(97.1)	(97.1)	2	(100.0)	36	(97.2)
Vermont	8	8	(100.0)	(100.0)	0	...	8	(100.0)
Virginia	332	304	(84.9)	(94.4)	2	(100.0)	306	(94.4)
Washington	250	235	(80.9)	(95.3)	1	(100.0)	236	(95.3)
West Virginia	21	17	(70.6)	(94.1)	0	...	17	(94.1)
Wisconsin	66	61	(86.9)	(93.4)	1	(100.0)	62	(93.5)
Wyoming	4	3	(100.0)	(100.0)	0	...	3	(100.0)
American Samoa ⁶
Fed. States of Micronesia ⁶
Guam ⁶	61	58	(87.9)	(96.6)	0	...	58	(96.6)
Marshall Islands ⁶
N. Mariana Islands ⁶
Puerto Rico ⁶	115	90	(70.0)	(86.7)	2	(0.0)	92	(84.8)
Republic of Palau ⁶
U.S. Virgin Islands ⁶

¹Most recent year for which data are available.

²Initial isolate susceptible to rifampin (n=9,762) or susceptibility unknown (n=412); culture negative (n=2,309); culture status unknown (n=720); age unknown (n=2).

³Initial isolate rifampin resistant, or pediatric patients (aged <15) with meningeal, bone, joint, or miliary disease.

⁴Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed, who did not die during therapy. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for reporting areas with information reported for ≥90% of cases.

⁵Excludes New York City.

⁶Not included in U.S. totals.

Note: Ellipses indicate data not available. See Technical Notes for description of Completion of Therapy calculation (page 9).